Analyzing MediPharm Labs (OTCMKTS:MEDIF) and Phathom Pharmaceuticals (NASDAQ:PHAT)

Phathom Pharmaceuticals (NASDAQ:PHAT) and MediPharm Labs (OTCMKTS:MEDIF) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Phathom Pharmaceuticals and MediPharm Labs’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
MediPharm Labs	N/A	N/A	N/A

Insider & Institutional Ownership

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Phathom Pharmaceuticals and MediPharm Labs”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11 million	4.10	-$221.25 million	($1.28)	-6.93
MediPharm Labs	N/A	N/A	N/A	N/A	N/A

MediPharm Labs has lower revenue, but higher earnings than Phathom Pharmaceuticals.

Analyst Ratings

This is a summary of recent recommendations and price targets for Phathom Pharmaceuticals and MediPharm Labs, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1	0	6	1	2.88
MediPharm Labs	0	0	0	0	0.00

Phathom Pharmaceuticals presently has a consensus target price of $22.86, suggesting a potential upside of 157.69%. Given Phathom Pharmaceuticals’ stronger consensus rating and higher possible upside, research analysts clearly believe Phathom Pharmaceuticals is more favorable than MediPharm Labs.

Summary

Phathom Pharmaceuticals beats MediPharm Labs on 7 of the 9 factors compared between the two stocks.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

About MediPharm Labs

MediPharm Labs Corp., a pharmaceutical company, engages in the production and sale of purified, pharmaceutical-quality cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower and pre-roll cannabis products. In addition, the company offers cannabis related medical information and services; and medical cannabis clinic services. MediPharm Labs Corp. was founded in 2015 and is headquartered in Barrie, Canada.